SEC Form 4 · accession 0001104659-26-075302
BioXcel Therapeutics, Inc. · BTAI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Javier Rodriguez
Officer — See Remarks
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 8:01 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001720893
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 15, 2026 | M | 35 | — | A | 26,838 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jun 15, 2026 | M | 35 | D | — | — | Common Stock | 35 | 212 | D |
Explanation of responses
- F1Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- F2On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
Remarks
Chief Legal Officer, Senior Vice President and Corporate Secretary